— Sarepta Therapeutics, Inc. (NASDAQ: SRPT) reported a loss of $1.57 per share in the fourth quarter of 2019, vs $1.86 per share loss expected.
— Q4 revenue rose 19% to $100.1 million, vs. $98.8 million expected. Results were helped by an increase in demand for EXONDYS 51 in the U.S.
— Appointed biotech executive John C. Martin to Board of Directors. He is a former Gilead CEO.
— SRPT shares ended Wednesday’s regular trading session down 1.14%.
Trxade Health Inc. (NASDAQ: MEDS) is an online pharmaceutical marketplace that provides a platform for independent pharmacies to operate more effectively. The company’s digital platform helps optimize drug procurement and
It is estimated that the size of the global chip manufacturing equipment market would nearly double from the current levels to about $142 billion in the next eight years. Applied
Shares of Take-Two Interactive Software (NASDAQ: TTWO) were down over 2% on Friday. The stock has dropped 32% year-to-date and 35% over the past 12 months. Earlier this week, the